Embecta Corp. EMBC R2KR3KPHARMA
Company Overview
Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. It primarily sells its products to wholesalers and distributors. The company was formerly known as Berra Newco, Inc. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.
Why Investors Should Care
Return on capital employed stands at 35.7%.
Trades at a P/E of 4.6, below the sector median of 25.4.
Operating margin of 23.7% supports profitability.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Sep 2025 Revenue of $1.08B (-3.8% YoY); net profit $95.40M.
- Trailing 12 Months Year-on-year growth — revenue -8.1%, earnings -53.7%.
- 5-Year Trend Long-term compounding — revenue CAGR -0.1%, profit CAGR -31.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -0.12% |
| 1 Year: | -8.10% |
Compounded Profit Growth
| 5 Years: | -31.27% |
| 1 Year: | -53.70% |
Stock Price Performance
| 1 Year: | -49.86% |
| 6 Months: | -26.85% |
| 3 Months: | +95.74% |
| 1 Month: | +19.40% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)67.41 · Neutral
P/E of 4.56 is below the sector median of 25.45 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Healthy ROCE of 35.7%.
- Generates positive free cash flow.
CONS
- Revenue declined at -0.1% CAGR over 5 years.
- Earnings shrank at -31.3% CAGR over 5 years.
- Trading 54.7% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | EMBC Embecta Corp. R2KR3KPHARMA | 6.71 | 4.56 | $380.19M | 0.70% | 35.74% | -14.66% | -0.12% | -31.27% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2020 | Mar 2021 | Jun 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 284.20M | 295.00M | 289.30M | 274.50M | 291.10M | 275.70M | 277.10M | 286.10M | 277.30M | 287.20M | 272.50M | 261.90M | 259.00M | 295.50M | 261.20M | 221.80M | 271.70M |
| Gross Profit | 191.30M | 196.30M | 202.60M | 203.90M | 191.20M | 202.90M | 188.80M | 189.80M | 189.50M | 185.90M | 185.40M | 190.10M | 157.10M | 164.10M | 197.10M | 161.70M | 127.80M | 153.30M |
| Operating Income | 124.10M | 126.40M | 124.30M | 116.60M | 98.90M | 97.10M | 88.80M | 55.60M | 51.30M | 45.50M | 39.20M | 55.90M | 28.70M | 62.90M | 94.00M | 83.30M | 35.00M | 48.70M |
| Net Income | 105.30M | 107.90M | 104.70M | 98.80M | 79.60M | 62.40M | 35.20M | 14.00M | 15.20M | 20.10M | 28.90M | 14.70M | 0 | 23.50M | 45.50M | 44.10M | -4.10M | 21.10M |
| Diluted EPS | - | 1.87 | 1.81 | 1.73 | 1.38 | 1.07 | 0.61 | 0.24 | 0.26 | 0.35 | 0.50 | 0.25 | 0.00 | 0.40 | 0.78 | 0.74 | -0.07 | 0.36 |
| R&D Expense | 14.00M | 14.10M | 15.70M | 16.70M | 18.00M | 14.30M | 16.90M | 22.10M | 22.60M | 20.20M | 18.40M | 20.40M | 20.30M | 8.00M | 4.40M | 4.60M | 5.40M | 5.60M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|
| Revenue | 1.09B | - | 1.13B | 1.12B | 1.12B | 1.08B |
| Cost of Revenue | - | - | 354.60M | 370.90M | 387.90M | 403.60M |
| Gross Profit | 762.60M | - | 774.90M | 749.90M | 735.20M | 676.80M |
| Operating Expenses | - | - | 406.40M | 525.90M | 450.20M | 380.40M |
| Operating Income | 486.50M | - | 368.50M | 224.00M | 285.00M | 296.40M |
| EBITDA | - | - | 334.50M | 245.30M | 192.70M | 284.30M |
| Interest Expense | - | - | 46.20M | 107.00M | 112.30M | 107.30M |
| Pretax Income | - | - | 256.60M | 105.70M | 44.20M | 136.30M |
| Tax Provision | - | - | 33.00M | 35.30M | -34.10M | 40.90M |
| Net Income | 427.60M | - | 223.60M | 70.40M | 78.30M | 95.40M |
| Diluted EPS | 7.50 | - | 3.89 | 1.22 | 1.34 | 1.62 |
| R&D Expense | 61.40M | 63.30M | 66.90M | 85.20M | 78.80M | 37.30M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 788.00M | 1.09B | 1.21B | 1.29B | 1.09B |
| Total Equity | 577.10M | 572.20M | 594.30M | -891.40M | -821.70M | -738.30M | -650.60M |
| Cash & Equivalents | - | - | 0 | 330.90M | 326.30M | 267.50M | 225.50M |
| Long Term Debt | - | - | 0 | 1.60B | 1.59B | 1.57B | 1.39B |
| Current Liabilities | - | - | 164.00M | 301.00M | 353.50M | 374.00M | 261.50M |
Cash Flows (Annual)
Figures in USD.
| Metric | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 498.50M | 456.30M | 412.20M | 67.70M | 35.70M | 191.70M |
| Investing Cash Flow | -41.90M | -39.20M | -24.00M | -26.50M | -15.80M | -9.30M |
| Financing Cash Flow | -456.60M | -417.10M | -48.00M | -48.70M | -73.40M | -226.70M |
| Capital Expenditure | -41.90M | -36.80M | -23.60M | -26.50M | -15.80M | -9.30M |
| Free Cash Flow | 456.60M | 419.50M | 388.60M | 41.20M | 19.90M | 182.40M |
Ratios (Annual)
Figures in %.
| Metric | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | 70.3% | - | 68.6% | 66.9% | 65.5% | 62.6% |
| Operating Margin % | 44.8% | - | 32.6% | 20.0% | 25.4% | 27.4% |
| Net Margin % | 39.4% | - | 19.8% | 6.3% | 7.0% | 8.8% |
| ROE % | 74.7% | - | -25.1% | -8.6% | -10.6% | -14.7% |
| ROCE % | - | - | 46.9% | 26.0% | 31.3% | 35.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 8.12% | 4.60M | $26.15M |
| 2 | Yacktman Asset Management Lp | 7.62% | 4.32M | $24.54M |
| 3 | Vanguard Capital Management LLC | 4.51% | 2.56M | $14.54M |
| 4 | Deerfield Management Company, L.P | 4.47% | 2.53M | $14.41M |
| 5 | Jefferies Financial Group Inc. | 4.16% | 2.36M | $13.39M |
| 6 | Ameriprise Financial, Inc. | 3.60% | 2.04M | $11.59M |
| 7 | Morgan Stanley | 3.52% | 2.00M | $11.35M |
| 8 | State Street Corporation | 2.84% | 1.61M | $9.16M |
| 9 | Geode Capital Management, LLC | 2.81% | 1.59M | $9.06M |
| 10 | Brigade Capital Management, LP | 2.68% | 1.52M | $8.62M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for EMBC
EMBC: Embecta Corp Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiSkFVX3lxTFBQNmpwQnV3c054dHBTMDN3LTNvOUtCVi1GVTFLUnVFZjBfUVlwNmpINkhYYnpyazBsdWF1ZmtkV3pyMUI4MU9PMU53?oc=5" target="_blank">EMBC: Embecta Corp Latest Stock Price, Analysis, News and Trading I…
Embecta (EMBC): Do Buybacks Amid Losses Reveal Capital Discipline or Strategic Uncertainty? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxOVGVaSjFkQ0xoWXlVdG1sa3pBYm1QWmJYR1dmdmhlY2x4QW5JQWV1d2VvLWN5STNPYk1Va3FTV2p6UTVrSnZsQW14ZkFzV29RcWhWSlB5TjNxdVhFVHJJV05pWlUxUE02U2VSekxTZHd4bUpidFp1MG04dUpDMXRDQlVkaWVjMGVCR0tUcW…
Embecta Corp. (EMBC): Deeply Undervalued Global Medical Device Company - The Acquirer's Multiple
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxPR0lFVTE2ZjlpOVVidDdwZmd1U1BHcS10cnhyZ09faWtHQ3UyLS1NOVFtdjlOaDQxak8tN2ZnUlQ3TEI4aS1NYWtGRGFhZEVObzFxaWMwUG1seHdaU1B4bGF6SFFfWUJJQWltZnRLQldha2lFQm1UUkNfb0F5d0k5c3ZvY19saUJ2TC14c1…
EMBC Stock News: Embecta Sued for Securities Fraud over Alleged Misrepresentations and Corresponding 57% Stock Drop - Morningstar
<a href="https://news.google.com/rss/articles/CBMihAJBVV95cUxOTWJJazZlT2EzVXpaZHdCNjY2dS1NOVVqUC1admNMRTV0eHF5b2JySGE2Z20zVTB0UFNmTnVXcXFHYmRWTkE3dXJpeFFTazVnZlZ3c1B2RUI2eTVmN2R2NGUtZ3poZGV0V0dFSjg1bEJCR25UY0lmRHZQUjZ1dVNRclh1c1UzVXRXMkNxVE…
EMBC Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE9nQ0xtYlh5cnJFNUkwZWtkZU9XY18yRVV3TEVCRGRLcTRxR2pURFVLMkZnOC1WSUh5cHd1anFaM1VZN0lLeEtZdGN3dkdFaC1CSFBmS2c4SWtEN2JWd2t2N0ZLaE85SkNlRTR1RHFUdzlGZU1KY0RncTZR?oc=5" target="_blank">EMB…
Embecta Corp. (NASDAQ:EMBC) Plunges Over 25% on Q2 Fiscal 2026 Miss - ChartMill
<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxQNWhkZjZWdEh5LTJKMXVIYjYyNjh4bTZ3RlBhMVZFWWd5MzVqX1pEREJGVGJYazRCamN1RWp1Rnc1SUFWYWdPSWRrNkZWSjAzOTJXazlrb0hjNVpvLS1NZG5TSG5jR1h1bjdoR1Y1bkQ5TlpwS1JOcjFYaVp5cmFzWXVMZ2dkeTZsekFXak…
EMBC — Frequently Asked Questions
What is the current share price of Embecta Corp. (EMBC)?
As of 2026-10-23 16:27 PDT, Embecta Corp. (EMBC) trades at $6.71 on NasdaqGS. Its 52-week range is $2.89 to $14.82.
What is the market capitalisation of EMBC?
Embecta Corp. (EMBC) has a market capitalisation of $380.19M on NasdaqGS.
What is the P/E ratio of EMBC?
EMBC trades at a trailing price-to-earnings (P/E) ratio of 4.56. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is -0.53.
Does EMBC pay a dividend?
Embecta Corp. (EMBC) currently offers a dividend yield of 0.70%.
What is the return on equity (ROE) of EMBC?
EMBC has a return on equity (ROE) of -14.66%. Its return on capital employed (ROCE) is 35.74%.
Is EMBC a good stock to buy?
This page provides a data-driven analysis of Embecta Corp. (EMBC), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.